Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae
Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae
复制标题
DOI：
10.1093/jac/dkr154
复制
发表时间：
2011-07-01
影响因子：
5.2
通讯作者：
Madrid, Peter
中科院分区：
文献类型：
--
作者：
Chopra, Sidharth;Matsuyama, Karen;Madrid, Peter
长期以来，快速生长的分枝杆菌在药物发现工作中一直被忽视，这种忽视反映在对这些感染引起的疾病缺乏可用的治疗选择上。本研究的目的是通过检测fda批准的药物对两种新出现的NTM耐药病原体脓肿分枝杆菌和龟分枝杆菌的抗菌活性，以确定治疗非结核分枝杆菌（NTM）的新候选药物。方法：在本研究中，我们筛选了1040种fda批准的抗脓疡分枝杆菌和chelonae的药物。结果：在筛选的药物中，32个化合物表现出显著的抗菌活性，具有MIC
Objectives: Rapidly growing mycobacteria have long been neglected in drug discovery efforts and this neglect is reflected in the paucity of therapeutic options available for diseases resulting from these infections. The purpose of this work is to identify new candidate drugs for treating non-tuberculous mycobacteria (NTM) by testing FDA-approved drugs for antimicrobial activity against Mycobacterium abscessus and Mycobacterium chelonae, two emerging NTM drug-resistant pathogens.Methods: In this study, we screened 1040 FDA-approved drugs against M. abscessus and M. chelonae.Results: Of the drugs screened, 32 compounds exhibited significant antimicrobial activity, with an MIC